Variables | DAS28 | SDAI | CDAI | ACR/EULAR Boolean | ACR/EULAR Boolean Practice | RAPID3 |
---|---|---|---|---|---|---|
Age, yrs | 1.00 (0.98–1.01) | 0.99 (0.98–1.00) | 0.99 (0.98–1.00)* | 0.99 (0.98–1.00)* | 0.99 (0.98–0.99)** | 0.98 (0.98–0.99)*** |
Female sex | 0.60 (0.49–0.73)*** | 0.72 (0.57–0.92)** | 0.76 (0.61–0.94)* | 0.80 (0.62–1.03) | 0.80 (0.64–1.01) | 0.97 (0.80–1.17) |
High education | 1.37 (1.09–1.73)** | 1.14 (0.90–1.46) | 1.14 (0.91–1.42) | 1.27 (0.99–1.63) | 1.16 (0.93–1.46) | 1.36 (1.13–1.64)** |
Erosive disease | 0.74 (0.60–0.91)** | 0.80 (0.62–1.04) | 0.83 (0.66–1.06) | 0.84 (0.64–1.09) | 0.91 (0.71–1.16) | 0.99 (0.81–1.21) |
Current smoking | 0.64 (0.52–0.82)*** | 0.64 (0.49–0.85)** | 0.69 (0.53–0.88)** | 0.71 (0.54–0.93)* | 0.76 (0.59–0.97)* | 0.94 (0.78–1.15) |
Disease duration, yrs, | ||||||
0–0.5 yr, reference | 1 | 1 | 1 | 1 | 1 | 1 |
> 0.5–1 | 0.89 (0.61–1.30) | 0.75 (0.46–1.22) | 0.83 (0.54–1.29) | 0.62 (0.36–1.07) | 0.70 (0.43–1.14) | 1.03 (0.73–1.46) |
> 1–5 | 0.64 (0.47–0.88)** | 0.76 (0.51–1.14) | 0.80 (0.56–1.15) | 0.75 (0.50–1.13) | 0.70 (0.48–1.02) | 0.84 (0.62–1.14) |
> 5–10 | 0.79 (0.55–1.12) | 0.69 (0.44–1.08) | 0.79 (0.52–1.20) | 0.73 (0.46–1.16) | 0.75 (0.49–1.15) | 0.91 (0.65–1.29) |
> 10 | 0.71 (0.51–1.00)* | 0.71 (0.47–1.08) | 0.75 (0.51–1.10) | 0.81 (0.54–1.23) | 0.76 (0.52–1.12) | 0.78 (0.56–1.07) |
Current treatment | ||||||
non-MTX DMARD, reference | 1 | 1 | 1 | 1 | 1 | 1 |
MTX monotherapy | 0.89 (0.71–1.12) | 1.08 (0.79–1.48) | 0.99 (0.74–1.33) | 0.97 (0.71–1.32) | 1.03 (0.77–1.37) | 0.91 (0.73–1.13) |
bDMARD | 1.52 (1.20–1.93)** | 1.86 (1.35–2.55)*** | 1.94 (1.46–2.58)*** | 1.57 (1.15–2.15)** | 1.61 (1.20–2.14)** | 1.26 (1.00–1.60)* |
mHAQ | 0.83 (0.66–1.06) | 0.60 (0.43–0.83)** | 0.56 (0.42–0.75)*** | 0.69 (0.49–0.95)* | 0.62 (0.46–0.84)** | 0.49 (0.35–0.69)*** |
Fatigue, per 10 mm | 0.94 (0.91–0.98)** | 0.89 (0.85–0.94)*** | 0.89 (0.86–0.93)*** | 0.90 (0.86–0.95)*** | 0.90 (0.86–0.94)*** | 0.88 (0.85–0.92)*** |
Previous DMARD use | 0.69 (0.53–0.91)** | 0.72 (0.50–1.04) | 0.64 (0.46–0.90)** | 0.76 (0.53–1.10) | 0.80 (0.56–1.12) | 0.64 (0.49–0.84)** |
↵* p < 0.05.
↵** p < 0.01.
↵*** p < 0.001. DMARD: disease-modifying antirheumatic drug; DAS28: Disease Activity Score at 28 joints; SDAI: Simplified Disease Activity Index; CDAI: Clinical Disease Activity Index; ACR: American College of Rheumatology; EULAR: European League Against Rheumatism; ACR/EULAR Boolean: ACR/EULAR Boolean remission definition; ACR/EULAR Boolean Practice: ACR/EULAR Boolean remission definition for clinical practice; RAPID3: Routine Assessment of Patient Index Data; MTX: methotrexate; bDMARD: biological DMARD; mHAQ: modified Health Assessment Questionnaire.